Ajanta Pharma has entered into an in-licensing agreement with Biocon for Semaglutide.
Under the agreement, Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, the Middle East and Central Asia. A GLP-1 receptor agonist, Semaglutide is to improve glycaemic control in adults. In a joint release, Ajanta Pharma and Biocon said the product patent expires in most of these markets in March 2026.
Ajanta plans to commercialise the products after receiving the regulatory approvals, which are expected in late 2026 or early 2027.
Ajanta Pharma managing director Yogesh Agrawal said “GLP-1 therapies have seen rapid global acceptance and have emerged as blockbuster products worldwide. We are excited to partner with Biocon for Semaglutide and take this important therapy to the markets where Ajanta has strong on-ground presence and deep reach. Confident of building Semaglutide into a meaningful and high-growth brand across these countries in the years ahead”.
Semaglutide is the active ingredient in Novo Nordisk’s diabetes and weight loss drugs Wegovy and Ozempic.
Published – December 23, 2025 10:45 pm IST
